

Regular Meeting of the

## Santa Clara County Health Authority Pharmacy & Therapeutics Committee

Thursday, March 18, 2021, 6:00 PM – 8:00 PM

Santa Clara Family Health Plan

6201 San Ignacio Ave, San Jose, CA 95119

# Minutes (Open) - Approved

---

### Members Present

Jimmy Lin, MD, Chair  
Ali Alkoraishi, MD  
Hao Bui, BS, RPh  
Dang Huynh, PharmD, Director of Pharmacy and UM  
Laurie Nakahira, DO, Chief Medical Officer  
Peter Nguyen, DO  
Jesse Parashar-Rokicki, MD

### Members Absent

Xuan Cung, PharmD  
Dolly Goel, MD  
Narinder Singh, PharmD

### Staff Present

Duyen Nguyen, PharmD, Clinical Pharmacist  
Tami Otomo, PharmD, Clinical Pharmacist  
Charlene Luong, Manager, Grievance &  
Appeals  
Nancy Aguirre, Administrative Assistant

### Others Present

Amy McCarty, PharmD, MedImpact

### 1. Roll Call

Jimmy Lin, MD, Chair, called the meeting to order at 6:06 pm. Roll call was taken and a quorum was established.

### 2. Public Comment

There were no public comments.

### 3. Meeting Minutes

The 4Q2020 P&T Committee Open meeting minutes were reviewed.

**It was moved, seconded and** the open minutes of the December 17, 2020 P&T meeting were **unanimously approved**.

**Motion:** Dr. Alkoraishi

**Second:** Dr. Nakahira

**Ayes:** Ms. Bui, Dr. Huynh, Dr. Lin, Dr. Nguyen, Dr. Parashar-Rokicki,

**Absent:** Ms. Cung, Dr. Goel, Dr. Singh

#### 4. Standing Agenda Items

##### a. Chief Medical Officer Health Plan Updates

Laurie Nakahira, DO, Chief Medical Officer (CMO), presented the CMO Health Plan Updates. SCFHP is currently in the Department of Health Care Services (DHCS) audit, which started on March 8, 2021 and will close tomorrow.

Dr. Nakahira announced a staffing change within the Case Management (CM) department. Raman Singh resigned as CM Director on March 10, 2020. Angela Chen, Utilization Management (UM) Manager, is CM certified and on the Board of CM Association in San Jose, CA. Ms. Chen has accepted the interim CM Director role.

Dr. Nakahira reported Santa Clara County is currently in the red tier. Some indoor dining and operations are permitted. There are currently three (3) COVID-19 vaccines available: Pfizer, Moderna, and Johnson & Johnson (J&J). Discussions with the Public Health Department reveal J&J will be utilized for members who are homebound and members who have trouble accessing the second vaccine.

##### b. Annual P&T Charter Review

Dang Huynh, PharmD, Director, Pharmacy & Therapeutics and UM presented the annual P&T Charter. There were no revisions made.

**It was moved, seconded and the P&T Charter was unanimously approved.**

**Motion:** Dr. Lin

**Second:** Dr. Nguyen

**Ayes:** Dr. Alkoraishi, Ms. Bui, Dr. Huynh, Dr. Nakahira, Dr. Parashar-Rokicki,

**Absent:** Ms. Cung, Dr. Goel, Dr. Singh

##### c. Medi-Cal Rx Update

Dr. Huynh presented the Medi-Cal (MC) Rx Update. The original DHCS go-live date was April 1, but was postponed due to discussions of potential conflict of interest, as Centene purchased Magellan for 2.2 billion dollars and owns Health Net. DHCS will provide an update in May, 2021.

##### d. Grievance & Appeals Report – 4Q 2020

Charlene Luong, Manager, Grievance & Appeals (G&A) presented the G&A Report for 4Q2020. Ms. Luong reviewed the MC and Cal MediConnect (CMC) appeals by volume and disposition as well as the MC appeal overturn rationale and uphold rationale.

##### e. Annual Policy Review

Dr. Huynh reported no changes were made to the following policies:

- i. PH.01 Pharmacy and Therapeutics Committee
- ii. PH.02 Formulary Development and Guideline Management
- iii. PH.03 Prior Authorization
- iv. PH.04 Pharmacy Clinical Programs and Quality Monitoring
- v. PH.05 Continuity of Care for Pharmacy Services
- vi. PH.06 Pharmacy Communications
- vii. PH.07 Drug Recalls
- viii. PH.08 Pain Management Drugs for Terminally Ill
- ix. PH.09 Medications for Members with Behavioral Health Conditions
- x. PH.11 340B Program Compliance
- xi. PH.14 Medications for Cancer Clinical Trial

**It was moved, seconded and the policies PH.01, PH.02, PH.03, PH.04, PH.05, PH.06, PH.07, PH.08, PH.09, PH.11, and PH.14 were unanimously approved.**

**Motion:** Dr. Alkoraishi

**Second:** Dr. Nguyen

**Ayes:** Ms. Bui, Dr. Huynh, Dr. Lin, Dr. Nakahira, Dr. Parashar-Rokicki,

**Absent:** Ms. Cung, Dr. Goel, Dr. Singh

**f. Plan/Global Medi-Cal Drug Use Review**

Tami Otomo, PharmD, Clinical Pharmacist, shared the results from SCFHP's quarterly retrospective Drug Use Evaluation (DUE) program. For Q12021, the focus was Coronary Artery Disease, specific to members with a history of an inpatient hospitalization and at least one (1) cardiovascular risk factor. SCFHP identified these members may benefit from a statin to reduce morbidity and mortality.

Dr. Otomo shared the providers of the impacted members will receive a letter in the mail regarding this program.

**g. Emergency Supply Report – 1Q 2020**

Duyen Nguyen, PharmD, Clinical Pharmacist, presented the Emergency Supply Report for 1Q2020. The approved claims for antibiotics were appropriate. For denied claims, chart notes were requested. One member had a denied claim for Cefixime 400mg capsule. This was identified as a gap and a point of sale (POS) message will be implemented for Cefdinir oral as a formulary alternative.

**Adjourned to Closed Session at 6:30 p.m.**

**Pursuant to Welfare and Institutions Code Section 14087.36 (w)**

**5. Closed Meeting Minutes**

The 4Q2020 P&T Committee Closed meeting minutes were reviewed.

**It was moved, seconded and the closed minutes of the December 17, 2020 P&T meeting were unanimously approved.**

**Motion:** Dr. Nguyen

**Second:** Dr. Nakahira

**Ayes:** Dr. Alkoraishi, Ms. Bui, Dr. Huynh, Dr. Lin, Dr. Parashar-Rokicki

**Absent:** Dr. Cung, Dr. Goel, Dr. Singh

**6. Metrics and Financial Updates**

**a. Membership Report**

Dr. Nakahira presented the Membership Report.

**b. Pharmacy Dashboard**

Dr. Otomo reviewed the Pharmacy Dashboard.

**c. Pharmacy Member Portal Stats – 2H 2020**

Dr. Huynh presented the Pharmacy Member Portal Stats.

**d. Drug Utilization & Spend – 4Q 2020**

Amy McCarty, MedImpact, presented the Drug Utilization and Spend for 4Q2020..

**7. Discussion and Recommendations for Changes to SCFHP's Cal MediConnect Formulary & Coverage Determination Criteria**

**a. Pharmacy Benefit Manager 4Q2020 P&T Minutes**

Dr. McCarty referenced the Pharmacy Benefit Manager 4Q2020 P&T Minutes.

**b. Pharmacy Benefit Manager 1Q2021 P&T Part D Actions**

Dr. McCarty reviewed the Pharmacy Benefit Manager 1Q2021 P&T Part D Actions.

**It was moved, seconded and the Pharmacy Benefit Manager 4Q2020 and 1Q2021 Part D Actions were unanimously approved.**

## 8. Discussion and Recommendations for Changes to SCFHP's Medi-Cal and Prior Authorization Criteria

### a. Old Business/Follow-Up

Dr. Huynh reported there were no old business items to report and/or follow-up.

### b. Formulary Modifications

Dr. Otomo presented the changes made to the Medi-Cal formulary since the last P&T Committee meeting in September 2020.

**It was moved, seconded and the Medi-Cal Formulary Modifications were unanimously approved.**

### c. Fee-for-Service Contract Drug List Comparability

Dr. McCarty reviewed the Fee-for-Service (FFS) Contract Drug List (CDL) Comparability for MC.

**It was moved, seconded and the Fee-for-Service Contract Drug List Comparability proposed actions were unanimously approved.**

### d. Prior Authorization Criteria

Dr. Nguyen reviewed the Prior Authorization Criteria.

#### i. New or Revised Criteria

1. Movantik (Naloxegol) – *added*

#### ii. Annual Review

1. Letairis (Ambrisentan) – *no changes*
2. Jadenu (Deferasirox) – *no changes*
3. Vumerity (Diroximel fumarate) – *no changes*
4. Gukenya (Fingolimod) – *no changes*
5. General utilization management – *no changes*
6. Copaxone (Glatiramer acetate) – *no changes*
7. Avonex & Rebif (Interferon beta-1a) – *no changes*
8. Savella (Milnacipran) – *no changes*
9. Opioid – Reauthorization – *no changes*
10. Oxycontin (Oxycodone) – *no changes*
11. Evista (Raloxifene) – *no changes*

***Peter Nguyen joined the meeting at approximately 7:21 p.m.***

**It was moved, seconded and the Prior Authorization Criteria was unanimously approved.**

## 9. New Drugs and Class Reviews

### a. Nexletol & Nexlizet - Hyperlipidemia

Dr. McCarty presented the new drugs and class reviews.

### b. Aducanumab – Alzheimer's Disease Review

Dr. McCarty reviewed Aducanumab – Alzheimer's Disease.

### c. COVID-19 Treatments

Dr. McCarty presented the COVID-19 treatments.

**It was moved, seconded and the recommendations for New Drugs and Class Reviews were unanimously approved.**

**d. Informational Only**

- i. Ponesimod – Multiple Sclerosis
- ii. Umbralisib – Lymphoma
- iii. Dasiglucagon – Hypoglycemia
- iv. New & Expanded Indications
- v. New Derivatives, Formulations, & Combinations

***Reconvene in Open Session at 7:37 p.m.***

**10. Discussion Items**

**a. New and Generic Pipeline**

Dr. McCarty reviewed the New and Generic Pipeline. Teplizumab (diabetes type 1 prevention) is currently under FDA review and will come to market in 3Q2021. MedImpact's projected monthly cost is approximately \$23,000 per month. Dr. Huynh will present the formulary status for MC line of business to the next P&T Committee meeting.

There were no notable generic drugs to review at this time.

***Ms. Bui announced her retirement from the P&T Committee after serving the committee since 1997. Within the 20+ years of service, Ms. Bui also served 12 years as a Board member on SCFHP's Governing Board. SCFHP thanks Ms. Bui for all her dedication and commitment to the P&T Committee, SCFHP, and the members within the community. Ms. Bui's participation is appreciated and will be missed.***

**11. Adjournment**

The meeting adjourned at 7:54 p.m. The next P&T Committee meeting will be on Thursday, June 17, 2021.

\_\_\_\_\_  
Jimmy Lin, MD, Chair

\_\_\_\_\_  
Date